DE | 13-3033811 | |
(State or other jurisdiction of | (IRS Employer | |
incorporation) | Identification No.) |
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Dr. Constantine, age 54, currently serves as Vice President of Women's Health & Bone Repair Medical Research at Wyeth Research, a division of Wyeth Pharmaceuticals, and has held Vice President positions with Wyeth since 2000.
There is no agreement or understanding between Dr. Constantine and any other person pursuant to which Dr. Constantine was appointed to the Board. Dr. Constantine is not a party to any tra nsaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K.
The Board has appointed Dr. Constantine to serve on its Nominating and Corporate Governance Committee.
Dr. Constantine shall receive compensation for serving on the Board and its committees pursuant to the Board compensation plan that was previously disclosed in the Company's filings with the SEC.
The full text of the press release issued in connection with Dr. Constantine's election to the Board is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
See Exhibit Index attached hereto.
Savient Pharmaceuticals, Inc. | ||||||||
Date: June 08, 2009 | By: | /s/ Philip K. Yachmetz | ||||||
Philip K. Yachmetz | ||||||||
SVP, General Counsel & Secretary | ||||||||
Exhibit No. | Description | |
EX-99.1 | Press Release dated June 5, 2009 |